Lagerwaard F J, Levendag P C
Department of Radiation Oncology, University Hospital Rotterdam, The Netherlands.
Forum (Genova). 2001 Jan-Mar;11(1):27-46.
Management of patients with brain metastases (BrM) has been evolving over time, with a general tendency towards a more aggressive treatment approach. Although whole brain radiotherapy (WBRT) remains the mainstay of treatment for the majority of patients, the indications for stereotactic radiosurgery (SRS) with or without WBRT have been expanding rapidly. In order to select patients who would benefit from the improved intracranial control rates obtained with advanced radiation therapy techniques, knowledge of prognostic factors is essential. Literature findings indicate that performance status, age and systemic tumour activity (extracranial metastases and primary tumour status) are the major determinants of survival for patients with BrM. Based on recursive partitioning analysis (RPA) of these factors, the Radiation Therapy Oncology Group has developed a prognostic classification system for patients with BrM. RPA Class 1 represents the most favourable subset of patients with Karnofsky performance status of > or = 70, age under 65 years, controlled primary tumour and no extracranial metastases. RPA Class 3 patients have KPS < 70, associated with poor median survival rates. RPA Class 2 contains the remainder of patients, a rather heterogeneous subset of patients with intermediate survival rates. This RPA classification system, which has been validated for patients treated with WBRT, surgery and SRS, respectively, appears to be a valuable tool for assessment of prognosis in patients with BrM.
脑转移瘤(BrM)患者的管理方法随着时间不断演变,总体趋势是治疗方法更积极。尽管全脑放疗(WBRT)仍然是大多数患者的主要治疗手段,但立体定向放射外科治疗(SRS)联合或不联合WBRT的适应证一直在迅速扩大。为了选择能从先进放疗技术提高的颅内控制率中获益的患者,了解预后因素至关重要。文献研究结果表明,体能状态、年龄和全身肿瘤活动情况(颅外转移和原发肿瘤状态)是BrM患者生存的主要决定因素。基于对这些因素的递归分割分析(RPA),放射肿瘤学组已为BrM患者制定了一个预后分类系统。RPA 1类代表最有利的患者亚组,卡诺夫斯基体能状态≥70、年龄<65岁、原发肿瘤得到控制且无颅外转移。RPA 3类患者的KPS<70,中位生存率较差。RPA 2类包含其余患者,这是一个生存率中等的相当异质性的患者亚组。这个分别已在接受WBRT、手术和SRS治疗的患者中得到验证的RPA分类系统,似乎是评估BrM患者预后的一个有价值的工具。